Global Alert and Response (GAR)

Report of a WHO consultation on medicinal and other products in relation to human and animal Transmissible Spongiform Encephalopathies. With the participation of the Office International des Epizooties (OIE). Geneva, Switzerland, 24-26 March 1997

WHO/EMC/ZOO/97/3/EN

Report of a WHO Consultation on Medicinal and other Products in Relation to Human and Animal Transmissible Spongiform Encephalopathies

Opening Remarks

1. Background Information on Transmissible Spongiform Encephalopathies (TSEs)

    1.1 Epidemiology and clinical features of Creutzfeldt-Jakob disease (CJD)
    1.2 Bovine spongiform encephalopathy (BSE)
    1.3 The nature of the agent
    1.4 New variant Creutzfeldt-Jakob disease (nvCJD)

2. Conclusions and Recommendations of the Consultation

    2.1 Measures to minimize risks to human from medicinal products and medical devices derived from bovine material
    Selection of source materials of bovine origin
    2.1.2 Type of bovine material
    2.1.3 Conditions under which materials are collected
    2.1.4 Procedures capable of reducing or removing infectivity
    2.1.5 Amount of bovine material
    2.1.6 Route of administration
    2.1.7 Comments
    2.2 Measures to minimize risks to humans from human derived material
    2.2.1 The risk of transmission of CJD by contaminated instruments, pituitary hormones and dura mater
    2.2.2 The risk of transmission of CJD by blood and blood products
    2.3. Minimizing risks related to food products from ruminant origin
    2.3.1 Safety of milk
    2.3.2 Risk of BSE occurring in sheep
    2.3.3 Gelatin in the food chain

ANNEX 1 - CATEGORIES OF INFECTIVITY IN BOVINE TISSUES AND BODY FLUID

ANNEX 2 - REFERENCES

Share
Email Twitter Facebook Google Delicious LinkedIn
More...